The Mevalonate Pathway in Streptococcus

链球菌中的甲羟戊酸途径

基本信息

  • 批准号:
    7193446
  • 负责人:
  • 金额:
    $ 52.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-04-01 至 2011-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Streptococcus pneumonia (SP) takes the lives of nearly 4000 people daily, the majority of whom are children below the age of five. The organism's ability to evolve resistance mechanisms has produced strains capable of tolerating our "last line of defense" antibiotics. This laboratory recently discovered that diphosphomevalonate (DPM), an intermediate in the mevalonate pathway, is a potent allosteric inhibitor of the SP mevalonate kinase (MK), and that it does not inhibit the human isozyme. The mevalonate pathway is essential for survival of the organism in mouse lung. DPM and the allosteric site offer a lead compound and target that provide an opportunity to develop a new class of antibiotics that could help eradicate this disease. Our preliminary data demonstrate that compounds based on these principles are capable of killing infectious SP in rich media. This proposal integrates structure, function and synthesis in a project designed to explore and define the three enzymes that comprise the mevalonate pathway in SP, and, in so doing, provide a basis for the design and synthesis of antibiotics. The information that this program will create is of considerable fundamental scientific value. Each of the three enzymes that comprise the pathway is a member of the GHMP kinase protein superfamily, whose biomedical relevance extends to both orphan diseases and cataract formation. We have determined the structure of MK from SP, and the structure of the DPM-inhibited complex with bound substrates is imminent. These structures define the MK-target and will reveal how DPM binding disrupts chemistry. We've also determined the structure of a ternary complex of phosphomevalonate kinase (PMK) from SP, which raises intriguing mechanistic issues that emphasize both the unique and familial structural elements of PMK. Diphosphomevalonate decaboxylase (DPM-DC) is a fascinating enzyme that decarboxylates DPM via a carbocationic transition-state. We will explore the DPM-DC mechanism by defining its transition-state structures and monitoring the formation of ligand and intermediate complexes to create an advanced catalytic paradigm for this mechanistic class.
描述(由申请人提供):肺炎链球菌(SP)每天夺走近4000人的生命,其中大多数是5岁以下的儿童。生物体进化耐药机制的能力已经产生了能够耐受我们的“最后一道防线”抗生素的菌株。本实验室最近发现,甲羟戊酸途径中的中间体二磷酸甲羟戊酸(diphosphomevalonate,DPHV)是SP甲羟戊酸激酶(MK)的有效变构抑制剂,并且它不抑制人同工酶。甲羟戊酸途径对于微生物在小鼠肺中的存活是必不可少的。它和变构位点提供了一种先导化合物和靶点,为开发一种新的抗生素提供了机会,这种抗生素可以帮助根除这种疾病。我们的初步数据表明,基于这些原则的化合物能够杀死富介质中的感染性SP。该建议将结构,功能和合成整合在一个旨在探索和定义SP中构成甲羟戊酸途径的三种酶的项目中,并为抗生素的设计和合成提供基础。这个项目将产生的信息具有相当大的基础科学价值。构成该途径的三种酶中的每一种都是GHMP激酶蛋白超家族的成员,其生物医学相关性延伸到孤儿病和白内障形成。我们已经确定了从SP MK的结构,并与绑定基板的DPM抑制复合物的结构是迫在眉睫。这些结构定义了MK靶点,并将揭示结合是如何破坏化学的。我们还确定了磷酸甲羟戊酸激酶(PMK)从SP,这引起了有趣的机制问题,强调PMK的独特和家族的结构元素的三元复合物的结构。二磷酸甲羟戊酸脱羧酶(DPM-DC)是一种通过碳阳离子过渡态使β-羟戊酸脱羧的酶。我们将通过定义其过渡态结构和监测配体和中间体络合物的形成来探索DPM-DC机制,从而为这一机制类创建先进的催化范例。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Thomas S. Leyh其他文献

Thomas S. Leyh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Thomas S. Leyh', 18)}}的其他基金

The Study of Human Sulfuryl-Transfer Biology
人类硫酰基转移生物学的研究
  • 批准号:
    10238022
  • 财政年份:
    2018
  • 资助金额:
    $ 52.51万
  • 项目类别:
The Study of Human Sulfuryl-Transfer Biology
人类硫酰基转移生物学的研究
  • 批准号:
    10472518
  • 财政年份:
    2018
  • 资助金额:
    $ 52.51万
  • 项目类别:
The Study of Human Sulfuryl-Transfer Biology
人类硫酰基转移生物学的研究
  • 批准号:
    10225670
  • 财政年份:
    2018
  • 资助金额:
    $ 52.51万
  • 项目类别:
Sulfotransferase Specificity and the Development of Sulfation Resistant Compounds
磺基转移酶特异性和抗硫酸化化合物的开发
  • 批准号:
    9199281
  • 财政年份:
    2014
  • 资助金额:
    $ 52.51万
  • 项目类别:
Sulfotransferase Specificity and the Development of Sulfation Resistant Compounds
磺基转移酶特异性和抗硫酸化化合物的开发
  • 批准号:
    8695910
  • 财政年份:
    2014
  • 资助金额:
    $ 52.51万
  • 项目类别:
Sulfotransferase Specificity and the Development of Sulfation Resistant Compounds
磺基转移酶特异性和抗硫酸化化合物的开发
  • 批准号:
    9103163
  • 财政年份:
    2014
  • 资助金额:
    $ 52.51万
  • 项目类别:
The Mevalonate Pathway in Streptococcus
链球菌中的甲羟戊酸途径
  • 批准号:
    7768421
  • 财政年份:
    2006
  • 资助金额:
    $ 52.51万
  • 项目类别:
The Mevalonate Pathway in Streptococcus
链球菌中的甲羟戊酸途径
  • 批准号:
    7082300
  • 财政年份:
    2006
  • 资助金额:
    $ 52.51万
  • 项目类别:
The Mevalonate Pathway in Streptococcus
链球菌中的甲羟戊酸途径
  • 批准号:
    7577482
  • 财政年份:
    2006
  • 资助金额:
    $ 52.51万
  • 项目类别:
The Mevalonate Pathway in Streptococcus
链球菌中的甲羟戊酸途径
  • 批准号:
    7365219
  • 财政年份:
    2006
  • 资助金额:
    $ 52.51万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 52.51万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.51万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 52.51万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.51万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 52.51万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 52.51万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.51万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 52.51万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 52.51万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.51万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了